Chief Scientific Officer Stephen Betz Sells Crinetics Pharmaceuticals Shares…

As disclosed in a recent SEC filing, Chief Science Officer Stephen Betz sold 3,000 shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock on June 25, 2024. Following the transaction, the insider now owns 80,643 shares of the company’s stock.

Crinetics Pharmaceuticals Inc is engaged in the discovery and development of novel drugs that target peptide hormone receptors for the treatment of endocrine-related diseases and cancers.

The insider has sold a total of 27,000 shares over the past year and made no purchases. The recent transaction is part of a broader trend at Crinetics Pharmaceuticals Inc, where there have been 26 insider sales and no insider purchases over the past year.

On the day of the transaction, shares of Crinetics Pharmaceuticals Inc were valued at $45.37, giving the company a market capitalization of approximately $3.33 billion. This valuation reflects various financial metrics, including the price-to-earnings ratio, price-to-sales ratio, price-to-book ratio, and price-to-free cash flow ratio.

Stock valuation can also be assessed using GF Value, a proprietary measure used to determine the fair value of a stock.

Insider selling trend at Crinetics Pharmaceuticals Inc. is an important indicator for potential investors, providing information about the actions of key executives and their views on the company’s stock.

This article, generated by GuruFocus, is intended to provide general insights and does not constitute tailored financial advice. Our commentary is based on historical data and analyst forecasts, is based on an unbiased methodology, and is not intended to serve as specific investment guidance. It does not make recommendations to buy or sell any stocks and does not take into account individual investment objectives or financial situations. Our goal is to provide long-term, fundamental, data-driven analysis. Please note that our analysis may not reflect the latest price-sensitive company announcements or qualitative information. GuruFocus does not have a position in the stocks mentioned in this document.

This article first appeared on GuruFocus.